Mederi draws $18.5M Series B to expand reach of GI treatment devices

Mederi Therapeutics grabbed $18.5 million in new financing to back an expanded commercial push for treatment devices that address gastroesophageal reflux disease and bowel incontinence. Acadia Woods Partners, Respiratory Diagnostics (a Bio-Rad Laboratory subsidiary) and a number of high-net-worth equity investors participated in the Series B financing, which involved preferred stock and venture debt. Greenwich, CT-based Mederi makes and sells medical devices that use radiofrequency energy to treat digestive system-related diseases. Item

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.